Triamcinolone

Generic Name: Triamcinolone

Brand Names: Allernaze, Aristocort, Aristocort R, Juulissa Pharmapak, Kenalog, Kourzeq, Marcaine, Nasacort, Oracort, Oralone, Pediaderm Ta, Triaderm, Trianex, Triderm, Triesence, Triloan Suik, Tritocin, Viaderm Kc, Xipere, Zilretta

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₇FO_₆

CAS Number: 124-94-7

Unique Ingredient Identifier: 1ZK20VI6TY

Background: Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly see...

Indication: 肾上腺皮质激素类药。主要用于过敏性与自身免疫性炎症性疾病。由于本品潴钠作用较弱，故一般不用作肾上腺皮质功能减退的替代治疗。

Associated Conditions: Acne, Acne Vulgaris, Acute Gouty Arthritis, Allergic Contact Dermatitis, Allergic Rhinitis (AR), Allergic Skin Reaction, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aphthous Stomatitis, Asthma, Atopic Dermatitis, Autoimmune Hemolytic Anemia, Berylliosis, Bullous dermatitis herpetiformis, Chronic Eczema, Chronic Inflammatory Skin Diseases, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Crohn's Disease (CD), Dental Cavity, Dermatitis, Dermatomyositis (DM), Diaper Rash, Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Erythroderma, Fungal Infections, Fungal infectious disorders of the Beard, Fungal skin infection, Gingivitis, Haemorrhoids, Hemangiomas, Hypercalcemia, Inflammation of Mouth, Intertrigo, Itching of the Anus, Itching of the External Genitalia, Itching of the Foot, Itching of the genitals, Itching of the hand, Juvenile Idiopathic Arthritis (JIA), Keloids Scars, Leukemias, Lichen Planus (LP), Lichen simplex chronicus, Lymphoma, Macular Edema, Mycosis Fungoides (MF), Mycotic Eczema, Necrobiosis lipoidica diabeticorum, Neurodermatitis, Nummular Dermatitis, Ocular Inflammation, Ophthalmia, Sympathetic, Oral Erosive Lichen Planus, Otitis Externa, Pemphigus, Pericarditis, Polymyositis, Postherpetic Neuralgia, Primary adrenocortical insufficiency, Proteinuria, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Psoriatic plaque, Pure Red Cell Aplasia, Purulent Wounds, Pyoderma caused by susceptible bacteria, Regional Enteritis, Rheumatoid Arthritis, Ringworm Folliculitis, Seborrheic Dermatitis, Seborrheic Dermatitis, Eczematous, Secondary Impetiginization, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Skin chapped, Stomatitis, Denture, Synovitis, Systemic Lupus Erythematosus, Temporal Arteritis, Tinea Corporis, Transfusion Reactions, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Urticaria, Uveitis, Wound Infections, Acute Bursitis, Acute Multiple sclerosis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Corticosteroid-responsive dermatoses, Cutaneous candidiasis, Cystic tumour of the ganglia, Exfoliative erythroderma, Granuloma annulare lesions, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Oral infections, Oral lesions, Severe Erythema multiforme, Subacute Dermatitis, Eczematous, Symptomatic Sarcoidosis, Ulceration of the mouth, Ulcerative stomatitis

Associated Therapies: -

Clinical Trials

Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema

Phase 3

Completed

Conditions: Diabetes Mellitus
Macular Edema

Interventions: Drug: Triamcinolone Acetonide
Procedure: Grid laser
Procedure: Sham Injection

First Posted Date: 2006-03-31

Last Posted Date: 2023-03-14

Lead Sponsor: Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA

Target Recruit Count: 292

Registration Number: NCT00309192

Locations: 🇪🇸
INGO - Instituto Galego de Oftalmoloxia, Santiago de Compostela, La Coruña, Spain
🇪🇸
Instituto Oftalmológico de Alicante, Alicante, Spain
🇪🇸
Hospital de la Vall D´Hebrón, Barcelona, Spain

and more 4 locations

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

Phase 3

Completed

Conditions: Macular Degeneration
Choroidal Neovascularization

Interventions: Drug: Verteporfin photodynamic therapy
Drug: Triamcinolone acetonide
Drug: Pegaptanib

First Posted Date: 2005-10-20

Last Posted Date: 2016-03-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 111

Registration Number: NCT00242580

Locations: 🇺🇸
Novartis Investigational Site, Austin, Texas, United States

PST/Laser v. Laser Alone for CSME

Phase 2

Conditions: Diabetic Retinopathy

First Posted Date: 2005-09-30

Last Posted Date: 2005-09-30

Lead Sponsor: Edward Hines Jr. VA Hospital

Target Recruit Count: 60

Registration Number: NCT00229918

Locations: 🇺🇸
Edward Hines Jr. VAH, Hines, Illinois, United States

Triamcinolone vs. Laser for Diabetic Macular Edema

Not Applicable

Completed

Conditions: DIABETIC MACULAR EDEMA

Interventions: Procedure: laser
Drug: Triamcinolone acetonide

First Posted Date: 2005-09-30

Last Posted Date: 2023-12-28

Lead Sponsor: University of Oklahoma

Target Recruit Count: 11

Registration Number: NCT00229931

Locations: 🇺🇸
Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States

Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.

Phase 2

Conditions: Age-Related Macular Degeneration

First Posted Date: 2005-09-08

Last Posted Date: 2007-07-30

Lead Sponsor: Canadian Retinal Trials Group

Target Recruit Count: 120

Registration Number: NCT00148551

Locations: 🇨🇦
Eye Care Centre, Vancouver, British Columbia, Canada

An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis

Phase 3

Completed

Conditions: Rhinitis, Allergic, Perennial

First Posted Date: 2005-08-22

Last Posted Date: 2011-01-11

Lead Sponsor: Sanofi

Target Recruit Count: 460

Registration Number: NCT00132925

Locations: 🇺🇸
Sanofi-Aventis, Inc., Bridgewater, New Jersey, United States

Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage

Phase 3

Completed

Conditions: Retinal Vein Occlusion
Macular Edema, Cystoid
Macular Edema

First Posted Date: 2005-03-21

Last Posted Date: 2008-03-04

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 1260

Registration Number: NCT00106132

Locations: 🇺🇸
National Eye Institute (NEI), Bethesda, Maryland, United States

Treatment of Diabetic Macular Edema: Triamcinolone Injections Vs. Laser Photocoagulation

Phase 3

Completed

Conditions: Diabetic Retinopathy
Diabetic Macular Edema
DME

First Posted Date: 2005-03-14

Last Posted Date: 2017-07-02

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 5

Registration Number: NCT00105404

Locations: 🇺🇸
National Eye Institute (NEI), Bethesda, Maryland, United States

Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders

Phase 1

Completed

Conditions: Macular Degeneration
Retinal Vein Occlusion
Diabetic Retinopathy

First Posted Date: 2005-01-13

Last Posted Date: 2017-07-02

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 120

Registration Number: NCT00101764

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration

Phase 3

Completed

Conditions: Macular Degeneration

First Posted Date: 2004-12-22

Last Posted Date: 2017-07-02

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 30

Registration Number: NCT00100009

Locations: 🇺🇸
Doheny Eye Institute, Los Angeles, California, United States
🇺🇸
Wills Eye Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Southeastern Retina Associates (SRAKT), Knoxville, Tennessee, United States

and more 19 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy